Keyhole-limpet hemocyanin [clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2]
Vaccination With Tetanus and KLH to Assess Immune Responses. [clinicaltrials:NCT00000105]Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation [clinicaltrials:NCT00002787]Vaccine Therapy in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00003638]clinicaltrials:NCT00003819clinicaltrials:NCT00004156Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma [clinicaltrials:NCT00004197]Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma [clinicaltrials:NCT00004198]Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy [clinicaltrials:NCT00004249]Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs [clinicaltrials:NCT00005000]Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer [clinicaltrials:NCT00006034]clinicaltrials:NCT00006478Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma [clinicaltrials:NCT00017290]Vaccine Therapy in Treating Patients With Multiple Myeloma [clinicaltrials:NCT00019097]Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC [clinicaltrials:NCT00026624]Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs [clinicaltrials:NCT00050921]Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma [clinicaltrials:NCT00091143]Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer [clinicaltrials:NCT00093522]clinicaltrials:NCT00282308Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer [clinicaltrials:NCT00329368]clinicaltrials:NCT00369291clinicaltrials:NCT00470574A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma [clinicaltrials:NCT00485563]clinicaltrials:NCT00536120clinicaltrials:NCT00614731clinicaltrials:NCT00643097clinicaltrials:NCT00923910Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes [clinicaltrials:NCT01082198]clinicaltrials:NCT01489956Keyhole Limpet Hemocyanin in Chronic Hepatitis C [clinicaltrials:NCT01509391]Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) [clinicaltrials:NCT01910662]Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects [clinicaltrials:NCT02079480]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Keyhole-limpet hemocyanin [clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2]
Bio2RDF identifier
d5ef4ca1260d86c18818dd4693482af2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2
identifier
clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2
title
Keyhole-limpet hemocyanin
@en
type
label
Keyhole-limpet hemocyanin [clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2]
@en